-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Jod0oPyEQdEkBbdGwd60vYhT2nKN4Zxt+/T8Hly6I4qhcCltLSRHapcYwoE3g8O2
 vHEzIkGsNBKUHcwnsQOIyA==

<SEC-DOCUMENT>0001181431-04-061200.txt : 20041230
<SEC-HEADER>0001181431-04-061200.hdr.sgml : 20041230
<ACCEPTANCE-DATETIME>20041229204503
ACCESSION NUMBER:		0001181431-04-061200
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041229
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041230
DATE AS OF CHANGE:		20041229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COTHERIX INC
		CENTRAL INDEX KEY:			0001138812
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50794
		FILM NUMBER:		041232339

	BUSINESS ADDRESS:	
		STREET 1:		5000 SHORELINE COURT
		STREET 2:		SUITE 101
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-808-6500

	MAIL ADDRESS:	
		STREET 1:		5000 SHORELINE COURT
		STREET 2:		SUITE 101
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXHALE THERAPEUTICS INC
		DATE OF NAME CHANGE:	20010503
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rrd62900.htm
<DESCRIPTION>SCHERING AMENDMENT
<TEXT>



<HTML>


<HEAD>








<TITLE> </TITLE>


<META NAME="subject" CONTENT=" ">


<META NAME="keywords" CONTENT=" ">


<META NAME="doccomm" CONTENT=" ">


</HEAD>


<BODY LINK="#0000ff" VLINK="#800080" BGCOLOR="#ffffff">





<FONT SIZE=2>


<B><P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">UNITED STATES </P>


<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION </P>


</B><P ALIGN="CENTER">Washington, D.C. 20549 </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">________________________</P>


</FONT><B><FONT SIZE=4><P ALIGN="CENTER">FORM 8K </P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">________________________</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">CURRENT REPORT</P>


<P ALIGN="JUSTIFY"></P><DIR>





<P ALIGN="CENTER">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">Date of report (date of earliest event reported):  December 29, 2004</P>


<P ALIGN="JUSTIFY"></P></DIR>





</FONT><B><FONT SIZE=5 COLOR="#808080"><P ALIGN="CENTER">CoTherix, Inc.</P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">(Exact name of registrant as specified in its charter) </P>


<P ALIGN="JUSTIFY"></P></FONT>


<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=716>


<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=14><DIR>





<B><FONT SIZE=2><P>&#9;&#9;Delaware</DIR>


</B></FONT></TD>


<TD WIDTH="22%" VALIGN="TOP" HEIGHT=14>


<B><FONT SIZE=2><P ALIGN="CENTER">000-50794</B></FONT></TD>


<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=14>


<B><FONT SIZE=2><P ALIGN="CENTER">04-3513144</B></FONT></TD>


</TR>


<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=15><DIR>





<FONT SIZE=2><P ALIGN="CENTER">(State or other jurisdiction of incorporation or organization)</DIR>


</FONT></TD>


<TD WIDTH="22%" VALIGN="TOP" HEIGHT=15>


<FONT SIZE=2><P ALIGN="CENTER">(Commission File Number)</FONT></TD>


<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=15>


<FONT SIZE=2><P ALIGN="CENTER">(I.R.S. employer identification number)</FONT></TD>


</TR>


</TABLE>


</CENTER></P>





<FONT SIZE=2><P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">5000 Shoreline Court, Suite 101, South San Francisco, CA 94080</P>


</B><P ALIGN="CENTER">(Address of principal executive offices and zip code) </P>


<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">(650) 808-6500 </P>


</B><P ALIGN="CENTER">(Registrant's telephone number, including area code) </P>


<P ALIGN="JUSTIFY"></P>


<P>&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="RIGHT"><A NAME="toc"></A></P>


<P ALIGN="RIGHT"></P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P>Item 1.01  Entry into a Material Definitive Agreement</P>





</B><P>Effective December 29, 2004, CoTherix, Inc. (&quot;CoTherix&quot;) and Schering Aktiengesellschaft (&quot;Schering AG&quot;) agreed upon an amendment to the Development and License Agreement dated October 2, 2003.  </P>





<P>Pursuant to the amendment, the time period in which CoTherix has to pay Schering AG a $9 million milestone payment in connection with U.S. Food and Drug Administration approval of Ventavis<SUP>TM</SUP> (iloprost) Inhalation Solution has been increased from thirty business days to up to six months and thirty business days.  A copy of the applicable amendment is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>


<B>


<P ALIGN="JUSTIFY">Item 9.01.  Financial Statements and Exhibits</P>


<P ALIGN="JUSTIFY"></P>


</B><P ALIGN="JUSTIFY">(c)  Exhibits</P>


<P ALIGN="JUSTIFY"></P><DIR>


<DIR>


<DIR>


<DIR>





<P ALIGN="JUSTIFY">99.1&#9;Amendment #2 to Development and License Agreement, dated as of December 14, 2004, between CoTherix, Inc. and Schering Aktiengesellschaft, effective as of December 29, 2004.</P></DIR>


</DIR>


</DIR>


</DIR>





<P ALIGN="JUSTIFY"> </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed &quot;filed&quot; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="CENTER">SIGNATURES </P>


</B><P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Date:  December 29, 2004</P></FONT>


<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=288>


<TR><TD VALIGN="BOTTOM" COLSPAN=2>


<B><FONT SIZE=2><P>CoTherix, Inc.</B></FONT></TD>


</TR>


<TR><TD WIDTH="9%" VALIGN="TOP">


<FONT SIZE=2><P>By: </FONT><FONT SIZE=1>&nbsp;</FONT></TD>


<TD WIDTH="91%" VALIGN="BOTTOM">


<FONT SIZE=2><P>/s/ Christine Gray-Smith</FONT></TD>


</TR>


<TR><TD VALIGN="TOP" COLSPAN=2 HEIGHT=55>


<FONT SIZE=2><P ALIGN="JUSTIFY">Christine Gray-Smith</P>


<P ALIGN="JUSTIFY">Executive Vice President and Chief Financial Officer</P>


</FONT></TD>


</TR>


</TABLE>


</P>





<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="CENTER">&nbsp;</P>


<B><P ALIGN="CENTER">INDEX TO EHXIBITS FILED WITH</P>


<P ALIGN="CENTER">THE CURRENT REPORT ON FORM 8-K DATED DECEMBER 29, 2004</P>


<P ALIGN="CENTER"></P>


<U><P>Exhibit&#9;</U>&#9;&#9;<U>Description</P>


</U><P>&#9;</P><DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>





</B><P>99.1<B>&#9;</B>Amendment #2 to Development and License Agreement, dated as of December 14, 2004, between CoTherix, Inc. and Schering Aktiengesellschaft, effective as of December 29, 2004.</P>


<P ALIGN="JUSTIFY"></P>


<P>&nbsp;</P>


<B><P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P></DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</B></FONT></BODY>


</HTML>









</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rrd62900_2638.htm
<DESCRIPTION>SCHERING AMENDMENT #2
<TEXT>



<HTML>


<HEAD>








<TITLE>Briefbogen SAG (engl) / Formular-Nr. 1086-9e, Version 1.0</TITLE>


<META NAME="Template" CONTENT="J:\Standard\Vorlagen\sag_dots\BRF-EN.DOT">


</HEAD>


<BODY>





<FONT FACE="Arial" SIZE=3><P>&#9;</P>





<B><P>Exhibit 99.1</P>


</B>


<P>&nbsp;</P>


<P>&nbsp;</P>


<P>&nbsp;</P></FONT>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=676>


<TR><TD WIDTH="45%" VALIGN="TOP" ROWSPAN=7 HEIGHT=18>


<FONT FACE="Arial" SIZE=3><P><A NAME="Addressee"></A>CoTherix, Inc.</P>


<P>Mr. Donald Santel</P>


<P>CEO</P>


<P>5000 Shoreline Court</P>


<P>Suite 101</P>


<P>South San Francisco, California 94080</P>


<P>U.S.A.</P>


</FONT><FONT FACE="Arial" SIZE=2></FONT></TD>


<TD WIDTH="27%" VALIGN="TOP" ROWSPAN=7 HEIGHT=18><P></P></TD>


<TD WIDTH="29%" VALIGN="TOP" COLSPAN=3 HEIGHT=18>


<FONT FACE="Arial" SIZE=3><P>Schering AG</FONT></TD>


</TR>


<TR><TD WIDTH="29%" VALIGN="TOP" COLSPAN=3 HEIGHT=74>


<FONT FACE="Arial" SIZE=3><P><A NAME="Department"></A></FONT></TD>


</TR>


<TR><TD WIDTH="3%" VALIGN="TOP" HEIGHT=25>


<FONT FACE="Arial" SIZE=1><P>E:</FONT></TD>


<TD WIDTH="26%" VALIGN="TOP" COLSPAN=2 HEIGHT=25>


<FONT FACE="Arial" SIZE=1><P><A NAME="Mail"></A></FONT></TD>


</TR>


<TR><TD WIDTH="11%" VALIGN="TOP" COLSPAN=2 HEIGHT=13>


<FONT FACE="Arial" SIZE=1><P>T:    +49.30.468-</FONT></TD>


<TD WIDTH="18%" VALIGN="TOP" HEIGHT=13>


<FONT FACE="Arial" SIZE=1><P><A NAME="Telefon"></A>15431</FONT></TD>


</TR>


<TR><TD WIDTH="11%" VALIGN="TOP" COLSPAN=2 HEIGHT=13>


<FONT FACE="Arial" SIZE=1><P>       +49.30.468-</FONT></TD>


<TD WIDTH="18%" VALIGN="TOP" HEIGHT=13>


<FONT FACE="Arial" SIZE=1><P>11 11</FONT></TD>


</TR>


<TR><TD WIDTH="11%" VALIGN="TOP" COLSPAN=2 HEIGHT=13>


<FONT FACE="Arial" SIZE=1><P>F:    +49.30.468-</FONT></TD>


<TD WIDTH="18%" VALIGN="TOP" HEIGHT=13>


<FONT FACE="Arial" SIZE=1><P><A NAME="Telefax"></A>14086</FONT></TD>


</TR>


<TR><TD WIDTH="11%" VALIGN="TOP" COLSPAN=2 HEIGHT=22><P></P></TD>


<TD WIDTH="18%" VALIGN="TOP" HEIGHT=22><P></P></TD>


</TR>


</TABLE>





<TABLE CELLSPACING=0 BORDER=0 WIDTH=683>


<TR><TD WIDTH="17%" VALIGN="TOP">


<FONT FACE="Arial" SIZE=1><P>Your Ref.</FONT></TD>


<TD WIDTH="16%" VALIGN="TOP">


<FONT FACE="Arial" SIZE=1><P>Your letter dated</FONT></TD>


<TD WIDTH="38%" VALIGN="TOP">


<FONT FACE="Arial" SIZE=1><P>Our Ref. (please indicate when replying)</FONT></TD>


<TD WIDTH="30%" VALIGN="TOP">


<FONT FACE="Arial" SIZE=1><P>Date</FONT></TD>


</TR>


<TR><TD WIDTH="17%" VALIGN="TOP" HEIGHT=24>


<FONT FACE="Arial" SIZE=3><P><A NAME="IhreZeichen"></A></FONT></TD>


<TD WIDTH="16%" VALIGN="TOP" HEIGHT=24>


<FONT FACE="Arial" SIZE=3><P><A NAME="IhreNachrichtvom"></A></FONT></TD>


<TD WIDTH="38%" VALIGN="TOP" HEIGHT=24>


<FONT FACE="Arial" SIZE=3><P><A NAME="UnserZeichen"></A>RA/UK/Cie (4b1412_2)</FONT></TD>


<TD WIDTH="30%" VALIGN="TOP" HEIGHT=24>


<FONT FACE="Arial" SIZE=3><P><A NAME="Datum"></A>2004-12-14 </FONT></TD>


</TR>


</TABLE>





<B><FONT FACE="Arial" SIZE=3><P>Amendment # 2 to Development and License Agreement</P>


</B><P>Dear Don,</P>


<P ALIGN="JUSTIFY">We refer to the Development and License Agreement by and between CoTherix, Inc., South San Francisco, California (hereinafter &quot;CoTherix&quot; - formerly called 'Exhale Therapeutics, Inc.') and Schering dated October 2, 2003 as amended by Amendment # 1 dated November 4/22, 2004 (hereinafter the &quot;Agreement&quot;).</P>


<P ALIGN="JUSTIFY">It is set forth in Section 7.2 of the Agreement that, no later than thirty (30) Business Days from Regulatory Approval of the Product in the Field by the Health Regulatory Authority, CoTherix shall pay to Schering a milestone in the amount of USD 9 Mio. (the &quot;Approval Milestone&quot;). CoTherix has recently requested that the payment of this Approval Milestone be deferred by a period of six (6) months. Accordingly, we would be willing to accept a one time deferral of this payment of six (6) months to the effect that the Approval Milestone shall be payable within six (6) months and thirty (30) Business Days from the date of Regulatory Approval of the Product in the Field by the Health Regulatory Authority; such deferral, however, being contingent upon the following conditions:</P>


<OL>





<P ALIGN="JUSTIFY"><LI>Payment of the Approval Milestone must be made in the year 2005 in the event that Regulatory Approval of the Product in the Field by the Health Regulatory Authority occurs in the year 2004 or 2005; however, in no event will the approval milestone be payable prior to thirty (30) business days following Regulatory Approval; and</LI></P>


<P ALIGN="JUSTIFY"><LI>The Approval Milestone shall be increased to the amount of USD 9 Mio. plus 10% annualized simple interest calculated on the principal of 9 Mio. for the duration of the deferral; and</LI></P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY"><LI>CoTherix shall at no cost provide to Schering and grant to Schering an exclusive, sub-licensable license to use outside the Territory any and all data (excluding, for the avoidance of doubt, inventions or patent rights) which are generated by the contract research organization Magellan concerning the nebulizers HaloLite, ProDose and iNeb outside the Territory; and</LI></P>


<P ALIGN="JUSTIFY"><LI>Should Regulatory Approval have occurred and CoTherix's cash position goes below USD 10 Mio., the six (6)-months deferral shall be waived and the Approval Milestone shall be due upon the later of thirty (30) Business Days from the date of such Regulatory Approval or the date that is ten (10) Business Days after the date upon which CoTherix's cash position goes below USD 10 Mio.</LI></P></OL>





<P ALIGN="JUSTIFY">Unless indicated otherwise, all capitalized terms as used in this Amendment # 2 to the Agreement shall have the meaning as set forth in the Agreement.</P>


<P ALIGN="JUSTIFY">In all other respects, the terms of the Agreement will remain unchanged.</P>


<P ALIGN="JUSTIFY">If you agree to this amendment, please countersign, date and return to us the attached duplicate of this letter.</P>


<P>Sincerely yours<BR>


Schering Aktiengesellschaft</P>





<U><P>/s/ Dr. Klaus Menken</U>&#9;&#9;&#9;&#9;<U>/s/ Dr. Bernhard Firtz-Zieroth</U><BR>


Dr. Klaus Menken&#9;&#9;&#9;&#9;Dr. Bernhard Fritz-Zieroth</P>


<P>&#9;&#9;&#9;&#9;December 16, 2004</P>





<P>&#9;Accepted and agreed by</P>


<P>&#9;CoTherix, Inc.</P>


<P>&#9;</P>


<P>&#9;<U>/s/ Donald J. Santel</U>&#9;Donald J. Santel</P>


<P>&#9;Chief Executive Officer</P>


<P>&#9;Date: 29 December, 2004</P>


</FONT></BODY>


</HTML>









</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
